Research specialized in the field of hematology oncology over relatively recent years has revolutionized patient care and led to an array of chemotherapeutic agents approved by the Food and Drug Administration. Both oral and intravenous drug formulations have been marketed, including targeted therapies, for several hematologic disorders including acute and chronic leukemias, Hodgkin and non-Hodgkin’s lymphomas, multiple myeloma, and myelofibrosis. The primary focus of this chapter will include latest chemotherapy developments in hematology covering critical topics of pharmacology, pharmacokinetics/pharmacodynamics, and pivotal clinical studies addressing both labeled and off-labeled indications. Lastly, future directions will be addressed, where applicable, in this continuously evolving clinical field.
Keywords: Acute lymphoblastic leukemia, Anaplastic large cell lymphoma, Bone marrow transplant, Cancer, Chemotherapy, Chronic lymphocytic leukemia, Chronic myeloid leukemia, Hematology, Hodgkin lymphoma, Mantle cell lymphoma, Multiple myeloma, Myelofibrosis, Non-Hodgkin’s lymphoma, Oncology, T-cell lymphoma.